Questcor Pharmaceuticals Inc. (QCOR) announced Tuesday morning that it has acquired rights to develop Synacthen and Synacthen Depot in the U.S. from Novartis.
Questcor Pharmaceuticals gapped open sharply higher Tuesday, but gradually gave back gains over the course of the trading session. Shares ended the day higher by 5.40 at $42.11, with volume at over an 8-month high. The stock finished at nearly a 1-month high.
For comments and feedback: editorial@rttnews.com